[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Clinical trial NCT06479811 · RECRUITING

Trial details

NCT number: NCT06479811
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Sinonasal Neuroendocrine Carcinoma Nasopharyngeal Carcinoma Esthesioneuroblastoma Olfactory Neuroblastoma Somatostatin Receptor Positive Small Cell Lung Cancers Pheochromocytoma/Paragangliomas Kidney Cancers Head and Neck Tumors Gastrointestinal Neuroendocrine Tumors

Start date: 2025-08-19
Primary completion: 2029-01-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.